<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Maffei MV</submitter><pubmed_abstract>BackgroundMechanically ventilated COVID-19 acute respiratory distress syndrome (ARDS) patients often receive deeper sedation and analgesia to maintain respiratory compliance and minimize staff exposure, which incurs greater risk of iatrogenic withdrawal syndrome (IWS) and has been associated with worse patient outcomes. &lt;b>Objective:&lt;/b> To identify potential risk factors and differences in patient outcomes associated with the development of IWS in COVID-19 ARDS patients. &lt;b>Methods:&lt;/b> Retrospective analysis of ventilated COVID-19 ARDS intensive care unit (ICU) patients who received continuous intravenous (IV) analgesia and sedation for ≥5 days from March 2020-May 2021. Patients were classified as IWS and non-IWS based on receipt of scheduled oral sedative/analgesic regimens after cessat</pubmed_abstract><journal>Journal of pharmacy practice</journal><pagination>8971900221116178</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9357752</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Risk Factors Associated With Opioid/Benzodiazepine Iatrogenic Withdrawal Syndrome in COVID-19 Acute Respiratory Distress Syndrome.</pubmed_title><pmcid>PMC9357752</pmcid><pubmed_authors>Maffei MV</pubmed_authors><pubmed_authors>Kim A</pubmed_authors><pubmed_authors>Laehn S</pubmed_authors><pubmed_authors>Bianchini M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk Factors Associated With Opioid/Benzodiazepine Iatrogenic Withdrawal Syndrome in COVID-19 Acute Respiratory Distress Syndrome.</name><description>BackgroundMechanically ventilated COVID-19 acute respiratory distress syndrome (ARDS) patients often receive deeper sedation and analgesia to maintain respiratory compliance and minimize staff exposure, which incurs greater risk of iatrogenic withdrawal syndrome (IWS) and has been associated with worse patient outcomes. &lt;b>Objective:&lt;/b> To identify potential risk factors and differences in patient outcomes associated with the development of IWS in COVID-19 ARDS patients. &lt;b>Methods:&lt;/b> Retrospective analysis of ventilated COVID-19 ARDS intensive care unit (ICU) patients who received continuous intravenous (IV) analgesia and sedation for ≥5 days from March 2020-May 2021. Patients were classified as IWS and non-IWS based on receipt of scheduled oral sedative/analgesic regimens after cessat</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-05T08:56:17.576Z</modification><creation>2025-04-05T08:56:17.576Z</creation></dates><accession>S-EPMC9357752</accession><cross_references><pubmed>35930693</pubmed><doi>10.1177/08971900221116178</doi></cross_references></HashMap>